Order Article Reprints

Kristensen M, Kucharz K, Felipe Alves Fernandes E, Strømgaard K, Schallburg Nielsen M, Cederberg Helms HC, Bach A, Ulrikkaholm Tofte-Hansen M, Irene Aldana Garcia B, Lauritzen M, et al. Conjugation of Therapeutic PSD-95 Inhibitors to the Cell-Penetrating Peptide Tat Affects Blood–Brain Barrier Adherence, Uptake, and Permeation. Pharmaceutics. 2020; 12(7):661. https://doi.org/10.3390/pharmaceutics12070661

Kristensen, Mie, Krzysztof Kucharz, Eduardo Felipe Alves Fernandes, Kristian Strømgaard, Morten Schallburg Nielsen, Hans Christian Cederberg Helms, Anders Bach, Malte Ulrikkaholm Tofte-Hansen, Blanca Irene Aldana Garcia, Martin Lauritzen, and et al. 2020. "Conjugation of Therapeutic PSD-95 Inhibitors to the Cell-Penetrating Peptide Tat Affects Blood–Brain Barrier Adherence, Uptake, and Permeation" Pharmaceutics 12, no. 7: 661. https://doi.org/10.3390/pharmaceutics12070661

Kristensen, M., Kucharz, K., Felipe Alves Fernandes, E., Strømgaard, K., Schallburg Nielsen, M., Cederberg Helms, H. C., Bach, A., Ulrikkaholm Tofte-Hansen, M., Irene Aldana Garcia, B., Lauritzen, M., & Brodin, B. (2020). Conjugation of Therapeutic PSD-95 Inhibitors to the Cell-Penetrating Peptide Tat Affects Blood–Brain Barrier Adherence, Uptake, and Permeation. Pharmaceutics, 12(7), 661. https://doi.org/10.3390/pharmaceutics12070661